Reevaluate metabolic status prior to discontinuing and restarting GLP-1 therapy, measure HbA1c, electrolytes, and fasting glucose and document any insulin requirements to assist in safe resumption
Over-the-counter medications can target specific side effects, such as nausea, vomiting, or constipation
The findings reveal that this development is real
Gastrointestinal adverse events were the most frequently reported side effects across all retatrutide dose groups , and they occurred primarily during the dose escalation phase of treatment
Weeks 1-4: 0.25 mg semaglutide + 5-10 mg pyridoxine, injected subcutaneously once weekly Weeks 5-8: 0.5 mg semaglutide + 5-10 mg pyridoxine, injected subcutaneously once weekly Weeks 9-12: 1.0 mg semaglutide + 5-10 mg pyridoxine, injected subcutaneously once weekly Weeks 13-16: 1.7 mg semaglutide + 5-10 mg pyridoxine, injected subcutaneously once weekly Week 17 and beyond: 2.4 mg semaglutide + 5-10 mg pyridoxine, injected subcutaneously once weekly Some providers modify this schedule based on individual tolerance
